MY133957A - "compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor" - Google Patents

"compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor"

Info

Publication number
MY133957A
MY133957A MYPI20010579A MYPI20010579A MY133957A MY 133957 A MY133957 A MY 133957A MY PI20010579 A MYPI20010579 A MY PI20010579A MY PI20010579 A MYPI20010579 A MY PI20010579A MY 133957 A MY133957 A MY 133957A
Authority
MY
Malaysia
Prior art keywords
adrenoceptor
alpha
prevention
treatment
disease mediated
Prior art date
Application number
MYPI20010579A
Other languages
English (en)
Inventor
Siegfried Wurster
Mia Engstrom
Liisa Huovinen
Sari Kalliokoski
Leila Kelanne
Eeva-Liisa Savola
Original Assignee
Oy Juvantia Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20000303A external-priority patent/FI20000303A0/fi
Application filed by Oy Juvantia Pharma Ltd filed Critical Oy Juvantia Pharma Ltd
Publication of MY133957A publication Critical patent/MY133957A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
MYPI20010579A 2000-02-11 2001-02-09 "compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor" MY133957A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18202100P 2000-02-11 2000-02-11
FI20000303A FI20000303A0 (fi) 2000-02-14 2000-02-14 Alfa-2B-adrenoseptorivälitteisen sairauden hoitoon tai ehkäisyyn käyttökelpoiset yhdisteet

Publications (1)

Publication Number Publication Date
MY133957A true MY133957A (en) 2007-11-30

Family

ID=26160944

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20010579A MY133957A (en) 2000-02-11 2001-02-09 "compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor"

Country Status (22)

Country Link
EP (1) EP1253926A1 (cs)
JP (1) JP2003522148A (cs)
KR (1) KR20020080413A (cs)
AU (1) AU780802B2 (cs)
BR (1) BR0108221A (cs)
CA (1) CA2399421A1 (cs)
CZ (1) CZ20022884A3 (cs)
EA (1) EA200200846A1 (cs)
EE (1) EE200200435A (cs)
GE (1) GEP20043356B (cs)
HR (1) HRP20020746A2 (cs)
HU (1) HUP0300032A3 (cs)
IL (1) IL151017A0 (cs)
IS (1) IS6476A (cs)
MX (1) MXPA02007454A (cs)
MY (1) MY133957A (cs)
NO (1) NO20023773D0 (cs)
NZ (1) NZ520500A (cs)
PL (1) PL357872A1 (cs)
SK (1) SK11472002A3 (cs)
WO (1) WO2001058454A1 (cs)
YU (1) YU59102A (cs)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI116940B (fi) 2001-07-20 2006-04-13 Juvantia Pharma Ltd Oy Alfa-2B-adrenoseptorivälitteisen sairauden hoitoon tai ehkäisyyn käyttökelpoiset yhdisteet
PL367040A1 (en) * 2001-07-20 2005-02-21 Oy Juvantia Pharma Ltd Compounds useful for treatment or prevention of disease mediated by alpha-2b-adrenoceptor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8416432D0 (en) * 1984-06-28 1984-08-01 Wyeth John & Brother Ltd Benzoquinolizines
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US6150389A (en) * 1994-07-11 2000-11-21 Allergan Sales, Inc. Comformationally rigid bicyclic and adamantane derivatives useful as α2 -adrenergic blocking agents

Also Published As

Publication number Publication date
WO2001058454A1 (en) 2001-08-16
AU3551001A (en) 2001-08-20
HUP0300032A3 (en) 2006-01-30
CZ20022884A3 (cs) 2003-02-12
IS6476A (is) 2002-07-19
KR20020080413A (ko) 2002-10-23
NZ520500A (en) 2005-01-28
CA2399421A1 (en) 2001-08-16
NO20023773L (no) 2002-08-09
EA200200846A1 (ru) 2002-12-26
BR0108221A (pt) 2003-03-05
IL151017A0 (en) 2003-02-12
EE200200435A (et) 2003-12-15
AU780802B2 (en) 2005-04-21
MXPA02007454A (es) 2004-08-23
HUP0300032A2 (en) 2003-05-28
SK11472002A3 (sk) 2003-02-04
JP2003522148A (ja) 2003-07-22
HRP20020746A2 (en) 2004-12-31
NO20023773D0 (no) 2002-08-09
EP1253926A1 (en) 2002-11-06
YU59102A (sh) 2005-11-28
PL357872A1 (en) 2004-07-26
GEP20043356B (en) 2004-04-13

Similar Documents

Publication Publication Date Title
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
WO2005011653A3 (en) Pyridazine derivatives and their use as therapeutic agents
HK1069339A1 (en) Substituted diketopiperazines as oxytocin antagonists
WO2003048164A3 (en) Adenosine a2a receptor antagonists
CA2427227A1 (en) Lactam compound
WO2004029031A3 (en) Therapeutic piperazine compounds
WO2005011655A3 (en) Pyridazine derivatives and their use as therapeutic agents
EA200501496A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
WO2005056524A3 (en) Therapeutic agents useful for treating pain
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
MXPA04005209A (es) Antagonistas del receptor de adenosina a2a.
WO2002088100A3 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
CA2378613A1 (en) Selective iglur5 receptor antagonists for the treatment of migraine
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
WO1999045909A3 (en) Use of nitrone compounds for the inhibition of angiogenesis
CA2432177A1 (en) Drug for prevention and/or therapy of endometriosis
MY133957A (en) "compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor"
SG165152A1 (en) Chemokine receptor antagonists and methods of use thereof
YU24603A (sh) Novi farmaceutski preparati koji sadrže epinastin i pseudoefedrin
DE60004996D1 (de) Aminotetralin derivate zur therapie der kardiovaskulären erkrankungen
ATE270886T1 (de) Antivirale therapie
ES2173044A1 (es) Glicina, n-(n-l- -glutamil-3-(nitrosotio)-l-valil) y sus aplicaciones.